Abstract:380 Background: Alternative mRNA splicing is recognized as a key driver of proteomic diversity. In cancer, this splicing process can be altered resulting in generation of aberrant splice variants (SvPs) that can contribute to tumor pathogenesis. However, our understanding of the significance of splice variants in clear cell renal cell carcinoma (ccRCC) is currently limited. Given the lack of actionable genomic mutations in ccRCC, aberrant SpVs may be the avenue to new pathogenic mechanisms and biomarkers. Methods: We implemented a novel pipeline to screen for and select SpVs frequent in and relatively specific to ccRCC. We started with RNA-seq data from the Cancer Cell Line Encyclopedia to identify SpVs specific to ccRCC cell lines. These were then screened across normal tissue in the Genotype-Tissue Expression Project (GTEx) and excluded if expressed. We analyzed bulk RNA-seq data of ccRCC primary tumors obtained from our institutional Total Cancer Care cohort (TCC; n = 111), The Cancer Genome Atlas (TCGA; n = 484) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC; n = 110) to analyze SpV expression in these samples. Using raw proteomics files from the CPTAC portal, proteins were identified and quantified using MaxQuant. Associations of SvP with protein expression were filtered by a Spearman correlation cutoff of +/-0.3. The Enrichr R library was used for pathway enrichment. Finally, we correlated splice variant expression with overall (OS) and cancer-specific survival (CSS). Using LASSO Cox regression analysis, we derived a SpV-based risk score trained on OS from the TCGA cohort and validated on the TCC and CPTAC cohorts. Results: Our pipeline selected 16 previously uncharacterized SpVs, including variants of suspected oncogenes and tumor suppressors. Proteogenomic analysis identified interesting biological associations. Among patients with high levels of EGFR SpV, we found significantly higher expression of the protein regulatory T cell marker CD70 (p adj = 0.03). MVK SvP was highly correlated with 25 proteins enriched for the mTOR pathway (p adj = 0.002). We derived a survival risk score based on expression of 5 SpVs ( PDZD2, COBLL1, PTPN14, RNASET2, FGD1) in the TCGA cohort. This risk score remained significant on multivariate analysis (HR 1.4, p = 0.002) adjusting for covariates including AJCC stage. This was validated on multivariate analysis in the TCC (HR 3.56, p < 0.001) and CPTAC (HR 3.18, p = 0.019) cohorts. Conclusions: Our novel pipeline selected 16 unique SpVs frequent in and relatively specific for ccRCC. Some are associated with proteins expressed in oncogenic pathways, suggesting a potential role in disease pathogenesis. Additionally, our SpV-based risk score is strongly associated with OS and CSS across multiple cohorts. This study provides a template for identifying and characterizing disease-specific aberrant SpVs to aid discovery of new mechanisms and biomarkers.

Genomic features defining exonic variants that modulate splicing

Computational Analysis Reveals a Correlation of Exon-Skipping Events with Splicing, Transcription and Epigenetic Factors.

The impact of genetically controlled splicing on exon inclusion and protein structure

Listening to silence and understanding nonsense: exonic mutations that affect splicing

Prioritizing Single-Nucleotide Variations That Potentially Regulate Alternative Splicing.

SpliceVarDB: A comprehensive database of experimentally validated human splicing variants

Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing

CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores

Regsnps-Splicing: a Tool for Prioritizing Synonymous Single-Nucleotide Substitution

Intronic Position +9 and −9 Are Potentially Splicing Sites Boundary from Intronic Variants Analysis of Whole Exome Sequencing Data

Proteogenomic and Clinical Implications of Unique Recurrent Splice Variants in Clear Cell Renal Cell Carcinoma.

Systematically developing a registry of splice-site creating variants utilizing massive publicly available transcriptome sequence data

ExonImpact: Prioritizing Pathogenic Alternative Splicing Events.

Assessing the Impact of Novel BRCA1 Exon 11 Variants on Pre-mRNA Splicing

A basic framework governing splice-site choice in eukaryotes

Chromatin and Genomic determinants of alternative splicing.

SpliceAPP: an interactive web server to predict splicing errors arising from human mutations

Widespread naturally variable human exons aid genetic interpretation

Machine Learning Approaches for the Prioritization of Genomic Variants Impacting Pre-mRNA Splicing

Experimental Assessment of Splicing Variants Using Expression Minigenes and Comparison with In Silico Predictions

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons